Risk of SARS-CoV-2 Infection in Patients with Hematologic Diseases Receiving Tixagevimab/cilgavimab As Pre-Exposure Prophylaxis in Most Recent Omicron Sublineages Era
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES(2024)
Key words
SARS-CoV-2,COVID-19,Hematologic disease,Pre-exposure prophylaxis,Tixagevimab/cilgavimab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined